These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34887866)

  • 1. SIRT1: A Potential Therapeutic Target in Autoimmune Diseases.
    Shen P; Deng X; Chen Z; Ba X; Qin K; Huang Y; Huang Y; Li T; Yan J; Tu S
    Front Immunol; 2021; 12():779177. PubMed ID: 34887866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
    Kong S; Yeung P; Fang D
    J Genet Genomics; 2013 Jul; 40(7):347-54. PubMed ID: 23876775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT1 and SIRT2: emerging targets in neurodegeneration.
    Donmez G; Outeiro TF
    EMBO Mol Med; 2013 Mar; 5(3):344-52. PubMed ID: 23417962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirtuin 1 in immune regulation and autoimmunity.
    Kong S; McBurney MW; Fang D
    Immunol Cell Biol; 2012 Jan; 90(1):6-13. PubMed ID: 22105513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How much successful are the medicinal chemists in modulation of SIRT1: A critical review.
    Kumar A; Chauhan S
    Eur J Med Chem; 2016 Aug; 119():45-69. PubMed ID: 27153347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal protective effect of sirtuin 1.
    Dong YJ; Liu N; Xiao Z; Sun T; Wu SH; Sun WX; Xu ZG; Yuan H
    J Diabetes Res; 2014; 2014():843786. PubMed ID: 25386563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas.
    Giry-Laterriere M; Pinho AV; Eling N; Chantrill L; Rooman I
    Curr Cancer Drug Targets; 2015; 15(6):463-8. PubMed ID: 26282546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Sirtuin-1 in Immune Response and Systemic Lupus Erythematosus.
    Qiu Y; Zhou X; Liu Y; Tan S; Li Y
    Front Immunol; 2021; 12():632383. PubMed ID: 33981300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators.
    Colak Y; Yesil A; Mutlu HH; Caklili OT; Ulasoglu C; Senates E; Takir M; Kostek O; Yilmaz Y; Yilmaz Enc F; Tasan G; Tuncer I
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):311-9. PubMed ID: 25267960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NLRP3 Inflammasome: Checkpoint Connecting Innate and Adaptive Immunity in Autoimmune Diseases.
    Zhang Y; Yang W; Li W; Zhao Y
    Front Immunol; 2021; 12():732933. PubMed ID: 34707607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two novel SIRT1 activators, SCIC2 and SCIC2.1, enhance SIRT1-mediated effects in stress response and senescence.
    Scisciola L; Sarno F; Carafa V; Cosconati S; Di Maro S; Ciuffreda L; De Angelis A; Stiuso P; Feoli A; Sbardella G; Altucci L; Nebbioso A
    Epigenetics; 2020; 15(6-7):664-683. PubMed ID: 31942817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Sirtuin 1 signaling pathway by ginsenosides.
    Lou T; Huang Q; Su H; Zhao D; Li X
    J Ethnopharmacol; 2021 Mar; 268():113657. PubMed ID: 33276056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirtuin 1 (SIRT1): the misunderstood HDAC.
    Stünkel W; Campbell RM
    J Biomol Screen; 2011 Dec; 16(10):1153-69. PubMed ID: 22086720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activators of SIRT1 in the kidney and protective effects of SIRT1 during acute kidney injury (AKI) (effect of SIRT1 activators on acute kidney injury).
    Raji-Amirhasani A; Khaksari M; Darvishzadeh Mahani F; Hajializadeh Z
    Clin Exp Nephrol; 2021 Aug; 25(8):807-821. PubMed ID: 33779856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Bichalcones as Sirtuin Inhibitors by Virtual Screening and In Vitro Testing.
    Karaman B; Alhalabi Z; Swyter S; Mihigo SO; Andrae-Marobela K; Jung M; Sippl W; Ntie-Kang F
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29443909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
    Choupani J; Mansoori Derakhshan S; Bayat S; Alivand MR; Shekari Khaniani M
    J Cell Physiol; 2018 Jun; 233(6):4443-4457. PubMed ID: 29194618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirtuin and metabolic kidney disease.
    Wakino S; Hasegawa K; Itoh H
    Kidney Int; 2015 Oct; 88(4):691-8. PubMed ID: 26083654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirt1 overexpression protects murine osteoblasts against TNF-α-induced injury in vitro by suppressing the NF-κB signaling pathway.
    Huang W; Shang WL; Wang HD; Wu WW; Hou SX
    Acta Pharmacol Sin; 2012 May; 33(5):668-74. PubMed ID: 22447223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders.
    Kauppinen A; Suuronen T; Ojala J; Kaarniranta K; Salminen A
    Cell Signal; 2013 Oct; 25(10):1939-48. PubMed ID: 23770291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. α7 Nicotinic Acetylcholine Receptor Relieves Angiotensin II-Induced Senescence in Vascular Smooth Muscle Cells by Raising Nicotinamide Adenine Dinucleotide-Dependent SIRT1 Activity.
    Li DJ; Huang F; Ni M; Fu H; Zhang LS; Shen FM
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1566-76. PubMed ID: 27339462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.